Senseonics Holdings, Inc.
US ˙ NYSEAM ˙ US81727U1051

Introduction

This page provides a comprehensive analysis of the known insider trading history of Peter Justin Klein. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Peter Justin Klein has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:PHAS / PhaseBio Pharmaceuticals Inc Director 14,000
US:SENS / Senseonics Holdings, Inc. Director 369,186
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Peter Justin Klein. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases SENS / Senseonics Holdings, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in SENS / Senseonics Holdings, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

SENS / Senseonics Holdings, Inc. Insider Trades
Insider Sales SENS / Senseonics Holdings, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in SENS / Senseonics Holdings, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

SENS / Senseonics Holdings, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Peter Justin Klein as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2021-06-04 2021-06-03 4 PHAS PhaseBio Pharmaceuticals Inc
Non-employee Director Stock Option (right to buy)
A - Award 14,000 14,000
2021-04-05 2021-04-01 4 SENS Senseonics Holdings, Inc.
Common Stock
A - Award 2,470 369,186 0.67 2.58 6,373 952,500
2021-01-06 2021-01-04 4 SENS Senseonics Holdings, Inc.
Common Stock
A - Award 6,853 366,716 1.90 0.93 6,375 341,119
2020-10-05 2020-10-01 4 SENS Senseonics Holdings, Inc.
Common Stock
A - Award 16,375 359,863 4.77 0.39 6,375 140,095
2020-08-20 2020-07-20 4/A SENS Senseonics Holdings, Inc.
Common Stock
A - Award 273,077 343,488 387.83
2020-07-22 2020-07-20 4 SENS Senseonics Holdings, Inc.
Common Stock
A - Award 273,077 343,488 387.83
2020-07-02 2020-07-01 4 SENS Senseonics Holdings, Inc.
Common Stock
A - Award 16,905 70,411 31.59 0.38 6,375 26,552
2020-06-05 2020-06-03 4 PHAS PhaseBio Pharmaceuticals Inc
Non-employee Director Stock Option (right to buy)
A - Award 16,000 16,000
2020-04-03 2020-04-01 4 SENS Senseonics Holdings, Inc.
Common Stock
A - Award 11,184 53,506 26.43 0.57 6,375 30,498
2020-01-06 2020-01-02 4 SENS Senseonics Holdings, Inc.
Common Stock
A - Award 6,959 42,322 19.68 0.92 6,374 38,767
2019-10-02 2019-10-01 4 SENS Senseonics Holdings, Inc.
Common Stock
A - Award 6,758 35,363 23.63 0.94 6,353 33,241
2019-07-03 2019-07-01 4 SENS Senseonics Holdings, Inc.
Common Stock
A - Award 3,286 28,605 12.98 1.94 6,375 55,494
2019-06-03 2019-05-30 4 SENS Senseonics Holdings, Inc.
Stock Option (right to buy)
A - Award 86,930 86,930
2019-05-13 2019-05-09 4 PHAS PhaseBio Pharmaceuticals Inc
Non-employee Director Stock Option (right to buy)
A - Award 11,000 11,000
2019-04-03 2019-04-01 4 SENS Senseonics Holdings, Inc.
Common Stock
A - Award 2,895 25,319 12.91 2.31 6,687 58,487
2019-03-01 2019-02-27 4 PHAS PhaseBio Pharmaceuticals Inc
Non-employee Director Stock Option (right to buy)
A - Award 36,000 36,000
2019-01-04 2019-01-02 4 SENS Senseonics Holdings, Inc.
Common Stock
A - Award 4,507 22,424 25.15 2.69 12,124 60,321
2018-10-24 2018-10-22 4 PHAS PhaseBio Pharmaceuticals Inc
Series B Preferred Stock
C - Conversion -2,303 0 -100.00
2018-10-24 2018-10-22 4 PHAS PhaseBio Pharmaceuticals Inc
Series B Preferred Stock
S - Sale -3 2,303 -0.13 5.00 -15 11,515
2018-10-24 2018-10-22 4 PHAS PhaseBio Pharmaceuticals Inc
Series B Preferred Stock
X - Other 103 2,306 4.68 0.12 12 277
2018-10-24 2018-10-22 4 PHAS PhaseBio Pharmaceuticals Inc
Warrants to Purchase Series B Preferred Stock
X - Other -103 0 -100.00
2018-10-24 2018-10-22 4 PHAS PhaseBio Pharmaceuticals Inc
Common Stock
C - Conversion 2,303 2,303
2018-10-03 2018-10-01 4 SENS Senseonics Holdings, Inc.
Common Stock
A - Award 2,670 17,917 17.51 4.54 12,122 81,343
2018-07-05 2018-07-02 4 SENS Senseonics Holdings, Inc.
Common Stock
A - Award 2,737 15,247 21.88 4.43 12,125 67,544
2018-06-01 2018-05-30 4 SENS Senseonics Holdings, Inc.
Stock Option (right to buy)
A - Award 50,847 50,847
2018-04-09 2018-04-02 4 SENS Senseonics Holdings, Inc.
Common Stock
A - Award 3,911 12,510 45.48 3.10 12,124 38,781
2018-01-04 2018-01-02 4 SENS Senseonics Holdings, Inc.
Common Stock
A - Award 4,558 8,599 112.79 2.66 12,124 22,873
2017-10-16 2017-10-12 4 SENS Senseonics Holdings, Inc.
Common Stock
A - Award 4,041 4,041
2017-05-26 2017-05-24 4 SENS Senseonics Holdings, Inc.
Stock Option (right to buy)
A - Award 128,817 128,817
2016-05-26 2016-05-24 4 SENS Senseonics Holdings, Inc.
Stock Option (right to buy)
A - Award 54,629 54,629
2016-03-17 3 SENS Senseonics Holdings, Inc.
Common Stock
7,784
2016-03-17 3 SENS Senseonics Holdings, Inc.
Common Stock
7,784
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)